Cannabis Extract Significantly Reduces Chemotherapy-Induced Vomiting, Tilray-Backed Study Reveals

On Thursday, Tilray Medical, a division of medical marijuana giant Tilray Brands, Inc. TLRY, announced the final results of a new scientific study, “Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV).” Results showed that cannabis extract significantly reduces chemotherapy-induced vomiting.

"These findings are encouraging for cancer patients undergoing chemotherapy," stated Denise Faltischek, chief strategy officer and head of international at Tilray Brands. "This study is a crucial step in improving patient care and quality of life. Our involvement in this study underscores our commitment to advancing medical research. The positive outcomes highlight the potential of cannabinoids for managing CINV.”

Read Also: Tilray, High Tide, Glass House: How Top Cannabis Companies Deal With Financial Pressures

Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.

Study Highlights

The randomized, placebo-controlled trial tested the effectiveness of an oral cannabis extract in adults suffering from CINV despite standard anti-nausea treatments. Participants received capsules containing 2.5 mg of THC and 2.5 mg of CBD or a placebo, taken three times daily for six days.

The study found the cannabis extract significantly improved the rate of complete response from 8% with placebo to 24% with THC: CBD, with no use of additional medications. Benefits included reduced nausea and fewer daily vomits.

However, some side effects were noted, such as sedation (18% vs. 7%), dizziness (10% vs. 0%), and transient anxiety (4% vs. 1%). From 2016 to 2022, 147 participants were recruited for the study.

Tilray Launches ‘Men's Health on Tap' Podcast

Meanwhile, Tilray Brands also announced the launch of “Men’s Health on Tap,” a new podcast series hosted by doctors, Dr. John P. Sfakianos, MD, associate professor, Department of Urology at the Icahn School of Medicine and Dr. Steven A. Kaplan, MD, professor, Department of Urology at the Icahn School of Medicine. The podcast aims to break down stigmas, open a conversation and and invite listeners to discuss important men’s health topics.

Sfakianos and Kaplan noted that many men hesitate to discuss health concerns and may delay visiting the doctor, which can lead to more serious, undiagnosed conditions. In episode one of the podcast, they encourage men to discuss these topics openly and emphasize that regular check-ups and early intervention can help them lead healthier, longer lives.

“We are excited to launch ‘Men’s Health on Tap’ and break down stigmas around men’s health,” stated Sfakianos. “Our goal is to provide valuable information and resources that will help men take control of their health and wellness.”

Price Action

Tilray shares traded 1.30% higher at $1.56 per share during Thursday's pre-market session

Read Next:

• Cannabis Giant Tilray Expands Medical Marijuana Portfolio With Redecan Launch In Australia

Photo: Courtesy of Tinnakorn jorruang via Shutterstock